Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Intranasal covid vaccine

5th International Conference and Exhibition on Pharmaceutical Development and Technology

Mr. Harshkumar Brahmbhatt

Charusat University, India

Keynote: Clin Pharmacol Biopharm

Abstract
The latest threat to global health is the ongoing outbreak of the respiratory disease that was recently given the name Coronavirus Disease 2019 (COVID- 19). It was rapidly shown to be caused by a novel coronavirus that is structurally related to the virus that causes severe acute respiratory syndrome (SARS). An intranasal vaccine stimulates a broad immune response â�?�? neutralizing IgG, mucosal IgA, and T cell responses. Immune responses at the site of infection (in the nasal mucosa) â�?�? essential for blocking both infection and transmission of COVID-19. Invading the mucosal surface by inducing local microbial-specific immune responses, nasal delivery of vaccines functions as a â�?�?first entry block,â�? i.e., block the pathogen entry, increasing the overall efficacy of the vaccine. Intranasal administration is a non-invasive route for drug delivery, which is widely used for the local treatment. The development of additional vaccine administration methods, including intranasal, oral, topical, pulmonary, vaginal, and rectal, is currently gaining traction in the vaccine market. The nasal route presents the most promising opportunity for vaccine administration. Convenience and safety can be improved, and it can also trigger both local and systemic immune responses, which could possibly offer protection from pathogens at the point of entry. The development of nasal vaccines presents both possibilities and difficulties. Keywords- Nasal Vaccines, Sars-CoV-2, iNCOVACC, Nasal Anatomy
Biography

Mr. Harshkumar Brahmbhatt has completed his Master of Pharmacy from Charusat University,changa,Gujarat,India. He has 2 years of experience as Scientist II at Torrent Pharmaceuticals Ltd,Gandhinagar,India and 4 years of experience in Acedamics and researcher as Assitant Professor at Department of Pharmacy, Sumandeep Vidyapeeth deemed to be University,Vadodara,India. He has received grant from GUJCOSTGujarat council on Science and Technology (a state goverment body) for the research work. He is director of Aryan crop Protection Pvt Ltd, Nadiad,Gujarat,India-A agriculture Products manufacturing company.

Top